Cargando…

Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making

Metastatic adenoid cystic carcinomas (ACCs) can cause significant morbidity and mortality. Because of their slow growth and relative rarity, there is limited evidence for systemic therapy regimens. Recently, molecular profiling studies have begun to reveal the genetic landscape of these poorly under...

Descripción completa

Detalles Bibliográficos
Autores principales: Chahal, Manik, Pleasance, Erin, Grewal, Jasleen, Zhao, Eric, Ng, Tony, Chapman, Erin, Jones, Martin R., Shen, Yaoqing, Mungall, Karen L., Bonakdar, Melika, Taylor, Gregory A., Ma, Yussanne, Mungall, Andrew J., Moore, Richard A., Lim, Howard, Renouf, Daniel, Yip, Stephen, Jones, Steven J.M., Marra, Marco A., Laskin, Janessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880267/
https://www.ncbi.nlm.nih.gov/pubmed/29610392
http://dx.doi.org/10.1101/mcs.a002626
_version_ 1783311135370379264
author Chahal, Manik
Pleasance, Erin
Grewal, Jasleen
Zhao, Eric
Ng, Tony
Chapman, Erin
Jones, Martin R.
Shen, Yaoqing
Mungall, Karen L.
Bonakdar, Melika
Taylor, Gregory A.
Ma, Yussanne
Mungall, Andrew J.
Moore, Richard A.
Lim, Howard
Renouf, Daniel
Yip, Stephen
Jones, Steven J.M.
Marra, Marco A.
Laskin, Janessa
author_facet Chahal, Manik
Pleasance, Erin
Grewal, Jasleen
Zhao, Eric
Ng, Tony
Chapman, Erin
Jones, Martin R.
Shen, Yaoqing
Mungall, Karen L.
Bonakdar, Melika
Taylor, Gregory A.
Ma, Yussanne
Mungall, Andrew J.
Moore, Richard A.
Lim, Howard
Renouf, Daniel
Yip, Stephen
Jones, Steven J.M.
Marra, Marco A.
Laskin, Janessa
author_sort Chahal, Manik
collection PubMed
description Metastatic adenoid cystic carcinomas (ACCs) can cause significant morbidity and mortality. Because of their slow growth and relative rarity, there is limited evidence for systemic therapy regimens. Recently, molecular profiling studies have begun to reveal the genetic landscape of these poorly understood cancers, and new treatment possibilities are beginning to emerge. The objective is to use whole-genome and transcriptome sequencing and analysis to better understand the genetic alterations underlying the pathology of metastatic and rare ACCs and determine potentially actionable therapeutic targets. We report five cases of metastatic ACC, not originating in the salivary glands, in patients enrolled in the Personalized Oncogenomics (POG) Program at the BC Cancer Agency. Genomic workup included whole-genome and transcriptome sequencing, detailed analysis of tumor alterations, and integration with existing knowledge of drug–target combinations to identify potential therapeutic targets. Analysis reveals low mutational burden in these five ACC cases, and mutation signatures that are commonly observed in multiple cancer types. Notably, the only recurrent structural aberration identified was the well-described MYB-NFIB fusion that was present in four of five cases, and one case exhibited a closely related MYBL1-NFIB fusion. Recurrent mutations were also identified in BAP1 and BCOR, with additional mutations in individual samples affecting NOTCH1 and the epigenetic regulators ARID2, SMARCA2, and SMARCB1. Copy changes were rare, and they included amplification of MYC and homozygous loss of CDKN2A in individual samples. Genomic analysis revealed therapeutic targets in all five cases and served to inform a therapeutic choice in three of the cases to date.
format Online
Article
Text
id pubmed-5880267
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-58802672018-04-13 Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making Chahal, Manik Pleasance, Erin Grewal, Jasleen Zhao, Eric Ng, Tony Chapman, Erin Jones, Martin R. Shen, Yaoqing Mungall, Karen L. Bonakdar, Melika Taylor, Gregory A. Ma, Yussanne Mungall, Andrew J. Moore, Richard A. Lim, Howard Renouf, Daniel Yip, Stephen Jones, Steven J.M. Marra, Marco A. Laskin, Janessa Cold Spring Harb Mol Case Stud Research Article Metastatic adenoid cystic carcinomas (ACCs) can cause significant morbidity and mortality. Because of their slow growth and relative rarity, there is limited evidence for systemic therapy regimens. Recently, molecular profiling studies have begun to reveal the genetic landscape of these poorly understood cancers, and new treatment possibilities are beginning to emerge. The objective is to use whole-genome and transcriptome sequencing and analysis to better understand the genetic alterations underlying the pathology of metastatic and rare ACCs and determine potentially actionable therapeutic targets. We report five cases of metastatic ACC, not originating in the salivary glands, in patients enrolled in the Personalized Oncogenomics (POG) Program at the BC Cancer Agency. Genomic workup included whole-genome and transcriptome sequencing, detailed analysis of tumor alterations, and integration with existing knowledge of drug–target combinations to identify potential therapeutic targets. Analysis reveals low mutational burden in these five ACC cases, and mutation signatures that are commonly observed in multiple cancer types. Notably, the only recurrent structural aberration identified was the well-described MYB-NFIB fusion that was present in four of five cases, and one case exhibited a closely related MYBL1-NFIB fusion. Recurrent mutations were also identified in BAP1 and BCOR, with additional mutations in individual samples affecting NOTCH1 and the epigenetic regulators ARID2, SMARCA2, and SMARCB1. Copy changes were rare, and they included amplification of MYC and homozygous loss of CDKN2A in individual samples. Genomic analysis revealed therapeutic targets in all five cases and served to inform a therapeutic choice in three of the cases to date. Cold Spring Harbor Laboratory Press 2018-04 /pmc/articles/PMC5880267/ /pubmed/29610392 http://dx.doi.org/10.1101/mcs.a002626 Text en © 2018 Chahal et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.
spellingShingle Research Article
Chahal, Manik
Pleasance, Erin
Grewal, Jasleen
Zhao, Eric
Ng, Tony
Chapman, Erin
Jones, Martin R.
Shen, Yaoqing
Mungall, Karen L.
Bonakdar, Melika
Taylor, Gregory A.
Ma, Yussanne
Mungall, Andrew J.
Moore, Richard A.
Lim, Howard
Renouf, Daniel
Yip, Stephen
Jones, Steven J.M.
Marra, Marco A.
Laskin, Janessa
Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title_full Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title_fullStr Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title_full_unstemmed Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title_short Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
title_sort personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880267/
https://www.ncbi.nlm.nih.gov/pubmed/29610392
http://dx.doi.org/10.1101/mcs.a002626
work_keys_str_mv AT chahalmanik personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT pleasanceerin personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT grewaljasleen personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT zhaoeric personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT ngtony personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT chapmanerin personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT jonesmartinr personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT shenyaoqing personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT mungallkarenl personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT bonakdarmelika personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT taylorgregorya personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT mayussanne personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT mungallandrewj personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT moorericharda personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT limhoward personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT renoufdaniel personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT yipstephen personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT jonesstevenjm personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT marramarcoa personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking
AT laskinjanessa personalizedoncogenomicanalysisofmetastaticadenoidcysticcarcinomausingwholegenomesequencingtoinformclinicaldecisionmaking